Go online to PeerView.com/DFX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This NCPD/ILNA-certified “Nurse Clinical Consults” webcast on antibody-based treatment options for patients with DLBCL, originally a live broadcast during the 2021 ONS Congress, features Lesley Camille Ballance, MSN, FNP-BC, Amy Goodrich, CRNP, and Jill Lozensky, RN, BSN, OCN. Hear what these experts have to say about educating patients on the clinical role of and efficacy expectations with novel antibodies for DLBCL; understanding safety considerations, such as infusion reactions, myelosuppression, and infections associated with antibody-based options; and counseling patients on appropriate dosing, treatment schedules, and clinical trials for R/R DLBCL. Upon completion of this accredited CE activity, participants should be better able to: Cite the current therapeutic role of novel antibody therapy, including CD19-, CD30-, CD79-, and CD20-directed agents, in relapsed diffuse large B-cell lymphoma (DLBCL), Discuss efficacy and safety evidence surrounding the use of antibody regimens in patients with DLBCL, Develop an education plan for patients with DLBCL focused on the efficacy and safety profiles of novel antibody-based treatments, Manage the unique spectrum of antibody-associated adverse events and dosing/administration considerations in the DLBCL setting.
View all episodes
